Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.

Autor: Simko F; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic; 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava 83305, Slovak Republic; Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava 84505, Slovak Republic. Electronic address: fedor.simko@fmed.uniba.sk., Stanko P; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic; Department of Pneumology, Phthisiology and Functional Diagnostics, Slovak Medical University and Bratislava University Hospital, Bratislava, Slovak Republic., Repova K; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic., Baka T; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic., Krajcirovicova K; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic., Aziriova S; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic., Domenig O; Attoquant Diagnostics, Vienna 1110, Austria., Zorad S; Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava 84505, Slovak Republic., Adamcova M; Department of Physiology, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove 50003, Czech Republic., Paulis L; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic; Centre of Experimental Medicine SAS, Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava 813 71, Slovak Republic.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Apr; Vol. 173, pp. 116391. Date of Electronic Publication: 2024 Mar 11.

Ivabradine curbs isoproterenol-induced kidney fibrosis.

Autor: Baka T; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Stanko P, Repova K, Aziriova S, Krajcirovicova K, Barta A, Zorad S, Simko F

Publikováno v: General physiology and biophysics [Gen Physiol Biophys] 2023 Mar; Vol. 42 (2), pp. 209-215.

Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril.

Autor: Repova K; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Stanko P; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Baka T; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Krajcirovicova K; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Aziriova S; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Hrenak J; Medbase, Bern, Switzerland., Barta A; Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia., Zorad S; Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Reiter RJ; Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX, United States., Adamcova M; Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia., Simko F; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.; Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.; 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2022 Sep 13; Vol. 13, pp. 978337. Date of Electronic Publication: 2022 Sep 13 (Print Publication: 2022).

Cardiovascular therapeutics: A new potential for anxiety treatment?

Autor: Repova K; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Aziriova S; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Krajcirovicova K; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Simko F; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.; 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.; Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.

Publikováno v: Medicinal research reviews [Med Res Rev] 2022 May; Vol. 42 (3), pp. 1202-1245. Date of Electronic Publication: 2022 Jan 06.

Ivabradine in the Management of COVID-19-related Cardiovascular Complications: A Perspective.

Autor: Baka T; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic., Repova K; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic., Luptak I; Cardiovascular Medicine Section, Boston University School of Medicine, Boston, MA, USA.; Myocardial Biology Unit, Boston University School of Medicine, Boston, MA, USA., Simko F; Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.; 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.; Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovak Republic.

Publikováno v: Current pharmaceutical design [Curr Pharm Des] 2022; Vol. 28 (19), pp. 1581-1588.